EA201001028A1 - Суспензия, содержащая немикронизированные микрочастицы эзетимиба - Google Patents

Суспензия, содержащая немикронизированные микрочастицы эзетимиба

Info

Publication number
EA201001028A1
EA201001028A1 EA201001028A EA201001028A EA201001028A1 EA 201001028 A1 EA201001028 A1 EA 201001028A1 EA 201001028 A EA201001028 A EA 201001028A EA 201001028 A EA201001028 A EA 201001028A EA 201001028 A1 EA201001028 A1 EA 201001028A1
Authority
EA
Eurasian Patent Office
Prior art keywords
microparticles
ezetimibe
suspension
suspension containing
unimicronized
Prior art date
Application number
EA201001028A
Other languages
English (en)
Other versions
EA017941B1 (ru
Inventor
Примоз Бенкиц
Матей Смрколь
Ален Кльайиц
Грегор Седмак
Original Assignee
Крка, Товарна Здравил, Д.Д., Ново Место
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40568477&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201001028(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Крка, Товарна Здравил, Д.Д., Ново Место filed Critical Крка, Товарна Здравил, Д.Д., Ново Место
Publication of EA201001028A1 publication Critical patent/EA201001028A1/ru
Publication of EA017941B1 publication Critical patent/EA017941B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates

Abstract

Настоящее изобретение относится к суспензии, содержащей немикронизированные микрочастицы эзетимиба, имеющие малый размер частиц и высокую удельную площадь поверхности, где указанные микрочастицы эзетимиба получают без процесса микронизации и где этот способ предотвращает вторичную агломерацию микрочастиц эзетимиба в суспензии. Суспензию немикронизированных микрочастиц эзетимиба можно непосредственно использовать в способе получения фармацевтической композиции. Настоящее изобретение относится к немикронизированным микрочастицам эзетимиба, имеющим малый размер частиц и высокую удельную площадь поверхности, которые могут быть выделены из суспензии.
EA201001028A 2007-12-17 2008-12-17 Суспензия, содержащая микрочастицы эзетимиба EA017941B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SI200700331 2007-12-17
SI200800017 2008-01-24
PCT/EP2008/067808 WO2009077573A2 (en) 2007-12-17 2008-12-17 Suspension comprising non-micronized ezetimibe micro-particles

Publications (2)

Publication Number Publication Date
EA201001028A1 true EA201001028A1 (ru) 2010-12-30
EA017941B1 EA017941B1 (ru) 2013-04-30

Family

ID=40568477

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201001028A EA017941B1 (ru) 2007-12-17 2008-12-17 Суспензия, содержащая микрочастицы эзетимиба

Country Status (5)

Country Link
EP (1) EP2231118B2 (ru)
CN (1) CN101938995A (ru)
AU (1) AU2008337435A1 (ru)
EA (1) EA017941B1 (ru)
WO (1) WO2009077573A2 (ru)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2708159C (en) 2007-12-10 2016-01-26 Ratiopharm Gmbh Pharmaceutical formulation comprising ezetimibe
CA2757722C (en) 2009-04-01 2018-05-22 Matrix Laboratories Ltd. Enzymatic process for the preparation of (s)-5-(4-fluoro-phenyl)-5-hydroxy- 1morpholin-4-yl-pentan-1-one, an intermediate of ezetimibe and further conversion to ezetimibe
BR112012002069B8 (pt) * 2009-07-28 2021-05-25 Egis Gyogyszergyar Nyilvanosan Muekodo Reszvenytarsasag processo para a fabricação de um granulado contendo ezetimibe microcristalino
EP2368543A1 (en) 2010-03-25 2011-09-28 KRKA, tovarna zdravil, d.d., Novo mesto Method of preparing a granulated pharmaceutical composition comprising simvastatin and/or ezetimibe
WO2013066279A1 (en) * 2011-10-13 2013-05-10 Mahmut Bilgic Solid dosage forms comprising ezetimibe
CN103877051B (zh) * 2014-04-19 2015-09-30 青岛科技大学 一种依折麦布片的制备方法
PL3256546T3 (pl) 2015-02-10 2020-03-31 Ciris Energy, Inc. Sposób depolimeryzacji
CN105503686A (zh) * 2015-12-31 2016-04-20 安徽美诺华药物化学有限公司 一种依替米贝的合成方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2344127C2 (ru) * 2000-11-30 2009-01-20 Тева Фамэситикл Индастрис Лтд. Новые кристаллические структуры (полиморфные модификации) полукальциевой соли аторвастатина и способы получения этих и других полиморфных модификаций соли аторвастатина
FR2834212B1 (fr) * 2001-12-27 2004-07-09 Besins Int Belgique Utilisation d'une poudre a liberation immediate dans des compositions pharmaceutiques et nutraceutiques
AR040588A1 (es) * 2002-07-26 2005-04-13 Schering Corp Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa
RU2005136987A (ru) * 2003-04-29 2006-03-20 Акцо Нобель Н.В. (NL) Способы, включающие применение кристаллизации с антирастворителем
WO2006060808A1 (en) * 2004-12-03 2006-06-08 Teva Pharmaceutical Industries Ltd. Ezetimibe polymorphs
EP1741427A1 (en) * 2005-07-06 2007-01-10 KRKA, D.D., Novo Mesto Pharmaceutical composition comprising simvastatin and ezetimibe

Also Published As

Publication number Publication date
CN101938995A (zh) 2011-01-05
AU2008337435A1 (en) 2009-06-25
EA017941B1 (ru) 2013-04-30
EP2231118A2 (en) 2010-09-29
EP2231118B1 (en) 2013-12-04
WO2009077573A2 (en) 2009-06-25
EP2231118B2 (en) 2017-05-17
WO2009077573A3 (en) 2010-03-18

Similar Documents

Publication Publication Date Title
EA201001028A1 (ru) Суспензия, содержащая немикронизированные микрочастицы эзетимиба
NZ716487A (en) Process for the preparation of n-[5-(3,5-difluoro-benzyl)-1h-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide
GEP20227369B (en) Antibodies specific for hyperphosphorylated tau and methods of use thereof
EA201171195A8 (ru) Конъюгаты, частицы, композиции "полимер-агент" и способы их применения
AU2016219704A1 (en) Anti-Notch1 antibodies
MY175260A (en) Prion free nanoparticle compositions and methods of making thereof
TN2015000076A1 (en) Methods of treating alzheimer's disease and pharmaceutical compositions thereof
MX357305B (es) Compuestos y composiciones para inhibir la actividad de abl-1, abl-2, y bcr-abl1.
MY161909A (en) Anti-her3 antibodies and uses thereof
WO2010007534A3 (en) Aqueous formulations
WO2011082266A3 (en) Substituted heterocyclic compounds
EA201171286A1 (ru) Новая технология изготовления индометацина
EA201390079A1 (ru) Пероральная лекарственная форма деферазирокса
WO2012165815A3 (ko) 종양 조직에서 유래한 나노소포체 및 이를 이용한 암 백신
NZ602578A (en) Polymorphic forms st-246 and methods of preparation
WO2010021717A3 (en) Hcv protease inhibitors
GB2496801A (en) A method of treating alzheimer's disease
NZ579478A (en) Epha3 antibodies for the treatment of solid tumors
PH12013500094A1 (en) Thiazolopyridin-2-yloxy-phenyl and thiazolopyrazin-2-yloxy-phenyl amines as modulators of leukotriene a4 hydrolase
WO2008061108A3 (en) Phthalazine derivatives
WO2014068586A3 (en) Solid oral compositions of tolvaptan
NZ730585A (en) Indolinone compounds and uses thereof
EA201300647A1 (ru) Оптимизированный синтез чистых неполиморфных кристаллических жёлчных кислот с заданным размером частиц
MX366829B (es) Composiciones y formas de dosificacion de itraconazol y metodos de uso de las mismas.
WO2011045760A3 (en) Micronized olmesartan medoxomil compositions

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU